Results, presented at the virtual AAT-AD/PD Focus Meeting in 2020, showed that although the vaccine was well-tolerated, it elicited a weak immune response (Alzforum.org, news; https://www.alzforum.org/news/conference-coverage/active-tau-vaccine-hints-slowing-neurodegeneration). Here, MAPT is linked to Alzheimer disease.